Medline Industries recalled 222,800 boxes of alcohol prep pads on September 29, 2025. The recall follows concerns the product may not meet potency standards. Consumers must stop using the pads and seek guidance from healthcare providers.
Subpotent Drug
Consumers and healthcare providers should stop using this product immediately. Contact Medline Industries, LP or your healthcare provider for guidance. Notification method: Letter
The recall affects Medline Alcohol Prep Pads, 2-Ply Pad, containing 70% Isopropyl Alcohol. Each box contains 100 pads, and there are 10 boxes per case, totaling 1,000 pads per case. They were distributed nationwide in the United States.
The recalled alcohol prep pads are classified as a subpotent drug. This means the pads may not effectively disinfect skin as intended, posing a risk during medical procedures.
There are no specific reported incidents or injuries associated with this recall. The potential for ineffective disinfection raises concerns for users.
Consumers and healthcare providers should stop using the recalled alcohol prep pads immediately. They can contact Medline Industries, LP for further guidance.
For more information, consumers can visit Medline's website or call the company directly at the contact number provided in their notification letter.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.